For example, in breast cancer, METTL3-mediated activation of PD-L1 mRNA is IGF2BP3-dependent, the METTL3/IGF2BP3 axis upregulates the m6A modification of PD-L1 mRNA, further increasing the stability of PD-L1 mRNA and inhibiting tumor immune surveillance [265]. This evidence concerns the gene IGF2BP3 and breast carcinoma.